Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
BPC-157 has shown strong results in tendon and ligament healing in rodent models accelerating repair and potentially reducing the extent of surgical intervention needed
Phase 1a: First-in-Human Single Ascending Dose Study (NCT02951806) Study Title: "Safety, Tolerability, and Pharmacokinetics of Single Doses of Cagrilintide in Healthy Subjects" Status: Completed Phase: Phase 1a Enrollment: 48 healthy volunteers Study Period: 2016-2017 Location: Single center (Denmark) Design: Randomized, double-blind, placebo-controlled, single ascending dose Dose Range: 0.03-10 mg SC Primary Endpoints: Safety, tolerability, PK parameters Population: Healthy male subjects, BMI 20-28 Key Results: Pharmacokinetics: Terminal half-life 5-7 days across dose range
The idea is that BPC 157 may support localized healing and inflammation control, while TB-500 may support tissue remodeling and repair-cell movement
coli K-12 and E
ISSN 0021-9738
US$ 24.26
US$ 28.30
US$ 24.65
